| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
| 2. Date of Event Requiring Statement (Month/Day/Year) 06/17/2022 | 3. Issuer Name and Ticker or Trading Symbol EKSO BIONICS HOLDINGS, INC. [ EKSO ] | |||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| 5. If Amendment, Date of Original Filed (Month/Day/Year) | ||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 20,632(1) | D | |
| Common Stock | 3,213 | I | By 401(k) |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (right to buy) | (2) | 08/28/2027 | Common Stock | 2,334 | 17.85 | D | |
| Stock Option (right to buy) | (3) | 07/13/2028 | Common Stock | 3,000 | 26.39 | D | |
| Explanation of Responses: |
| 1. Includes an aggregate of 19,250 time-based Restricted Stock Units ("RSUs") granted under the Company's Amended and Restated 2014 Equity Incentive Plan, as follows: i) 15,000 RSUs that were granted to the Reporting Person on August 1, 2021, 1/3 of which will vest on each of August 1, 2022, 2023 and 2024; ii) 4000 RSUs that were granted to the Reporting Person on November 6, 2019, 1/2 of which will vest on each of November 6, 2022 and 2023; and iii) 250 RSUs that were granted to the Reporting Person on July 13, 2018 and which will vest on July 13, 2022, in each case subject to the Reporting Person's continuous service with the issuer as of each vesting date. Each RSU represents the economic equivalent of one share of EKSO common stock and shall be settled in shares of EKSO common stock upon vesting. |
| 2. The option agreement provides that 1/4 of the option became exercisable beginning on the first anniversary of the option's grant date, and 1/36 vested in equal monthly installments thereafter. The option was granted on August 28, 2017. |
| 3. The option agreement provides that 1/4 of the option became exercisable beginning on the first anniversary of the option's grant date, with 1/36 vesting in equal monthly installments thereafter. The option was granted on July 13, 2018. |
| Remarks: |
| Exhibit 24.1 Power of Attorney |
| /s/ Jerome Wong | 06/22/2022 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
